Market Overview

Thermo Fisher Scientific to Sell its Cell Culture, Gene Modulation and Magnetic Beads Businesses to GE Healthcare for $1.06B

Related TMO
Markets Reverse Early Morning Gains Following Canadian Shooting
UPDATE: Thermo Fisher Posts Better-Than-Expected Q3 Earnings, Lowers Sales Forecast

Thermo Fisher Scientific (NYSE: TMO) today announced that it has signed an agreement to sell its
cell culture (sera and media), gene modulation and magnetic beads
businesses to GE Healthcare, a unit of General Electric Company (NYSE: GE), for approximately $1.06 billion. The businesses will become part of
GE Healthcare's Life Sciences division.

See full press release

Posted-In: News Guidance Asset Sales Management M&A Global

 

Related Articles (LIFE + GE)

Around the Web, We're Loving...

Get Benzinga's Newsletters